Current Report · Items 8.01, 9.01 · 8-K/A
Processa Pharmaceuticals, Inc.
Other Events
Item 8.01. Other Events The information set forth in the “Business Section of the Company” reflecting the business of the Company following the acquisition of Vidya is attached hereto as Exhibit 99.3 and incorporated herein by reference.…
Filed Oct 5, 2026Accepted Oct 5, 2026, 7:21 AM EDTCIK 1533743Accession 0001140361-26-038535
Company context
We are a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (“NGC”) small molecules, two of which are in, or have completed, Phase 2 trials, and one is in pre-clinical development.
Current securities
Historical securities (1)
Registered securities in this filing
Processa Pharmaceuticals, Inc. · 8-K/A · Filed 2026-10-05
As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.
Common Stock, $0.0001 par value per share
- Symbol
- PCSA
- Exchange
- NASDAQ
- Classification
- COMMON
Filing context
Context: c20260723to20260723
Dimensions: Not supplied
Accession 000114036126038535 · 1 registered-security cover member
Read the exact SEC filing ↗Disclosure sections
Items 8.01, 9.01Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events
The information set forth in the “Business Section of the Company” reflecting the business of the Company following the acquisition of Vidya is attached hereto as Exhibit 99.3 and incorporated herein by reference.
The information regarding the risks associated with the business and operations of the Company following the acquisition of Vidya set forth in the “Risk Factors of the Company” is attached hereto as Exhibit 99.4 and incorporated herein by
reference.